About Trillium Therapeutics (NASDAQ:TRIL)
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol:
- Market Cap: $64.76 million
- Outstanding Shares: 10,794,000
- 50 Day Moving Avg: $5.08
- 200 Day Moving Avg: $5.15
- 52 Week Range: $4.15 - $15.87
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.15
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.74 per share
- Price / Book: 3.91
- EBITDA: ($28,620,000.00)
- Return on Equity: -178.08%
- Return on Assets: -61.40%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 7.92%
- Quick Ratio: 7.92%
- Average Volume: 51,400 shs.
- Beta: 1.29
- Short Ratio: 20.39
Frequently Asked Questions for Trillium Therapeutics (NASDAQ:TRIL)
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
When will Trillium Therapeutics make its next earnings announcement?
Where is Trillium Therapeutics' stock going? Where will Trillium Therapeutics' stock price be in 2017?
5 brokerages have issued twelve-month price objectives for Trillium Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Trillium Therapeutics' stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Trillium Therapeutics.
What are analysts saying about Trillium Therapeutics stock?
Here are some recent quotes from research analysts about Trillium Therapeutics stock:
- 1. According to Zacks Investment Research, "Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. " (10/17/2017)
- 2. Cowen and Company analysts commented, "The key investor concern coming into ASH was safety of the 0.2mg/kg/week dose of." (12/5/2016)
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Protalix Biotherapeutics (PLX), ContraFect Corporation (CFRX), Concordia International Corp (CXR), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND) and Durata Therapeutics (DRTX).
How do I buy Trillium Therapeutics stock?
Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trillium Therapeutics' stock price today?
MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Trillium Therapeutics stock can currently be purchased for approximately $6.80.
Consensus Ratings for Trillium Therapeutics (NASDAQ:TRIL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||5 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$15.00 (120.59% upside)|Consensus Price Target History for Trillium Therapeutics (NASDAQ:TRIL)
Analysts' Ratings History for Trillium Therapeutics (NASDAQ:TRIL)
(Data available from 10/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/14/2017||HC Wainwright||Set Price Target||Buy||$7.00||Medium|
|7/5/2017||Cowen and Company||Reiterated Rating||Buy||Medium|
|6/9/2017||Ladenburg Thalmann Financial Services||Reiterated Rating||Buy||$18.00||Low|
|11/4/2016||Bloom Burton||Reiterated Rating||Buy||N/A|
|11/3/2016||Leerink Swann||Reiterated Rating||Outperform||$20.00||N/A|
|10/6/2016||BTIG Research||Initiated Coverage||Buy||$21.00||N/A|
|6/6/2016||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$38.00||N/A|
Earnings History for Trillium Therapeutics (NASDAQ:TRIL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Trillium Therapeutics (NASDAQ:TRIL)
2017 EPS Consensus Estimate: ($2.98)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Trillium Therapeutics (NASDAQ:TRIL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Trillium Therapeutics (NASDAQ:TRIL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Trillium Therapeutics (NASDAQ:TRIL)
Latest Headlines for Trillium Therapeutics (NASDAQ:TRIL)
Trillium Therapeutics (TRIL) Chart for Wednesday, October, 18, 2017